Aktuelle Studien

Urologie

Direktor:
Prof. Dr. med. Bernd Wullich

Aktuelle Studien

Niere         
RCC

Epidemiologisches Register zur Darstellung der Behandlungsrealität und der Therapiemodalitäten beim behandlungsbedürftigen metastasierten oder lokal fortgeschrittenen Nierenzellkarzinom

STAR – TOR

Registerstudie|Register zur Bewertung der Sicherheit, Verträglichkeit und Wirksamkeit von Sunitinib (Sutent®), Axitinib (Inlyta®) und Temsirolimus (Torisel®) in der Behandlung von Patienten mit fortgeschrittenem Nierenzellkarzinom

F-FR-60000-023: (Start noch offen) A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS
Sunniforecast

A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma

Prostata
C3441021_TALAPRO-2: (Start noch offen)A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER
MK 7339-010: (Start noch offen)A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
PCOProstate Cancer Outcomes – Compare & Reduce Variation in DKG-zertifizierten Prostatakrebszentren
Rhovav002PM-WPD-003-001_Linical: (Start noch offen)A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy For Localized Prostate Cancer
Blase
BAY17403_FORT-1A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinumcontaining chemotherapy
BLC3001_THORA Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
CA045-009A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible.
MK 3475-866Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy vs. Placebo + Neoadjuvant Chemotherapy in Cisplatin Eligible Patients with Muscle-invasive Bladder Cancer (MIBC)
Moni-TURBProject1-MoniTURB-Prediction of necessity of 2nd TURB by molecular analysis of urine and/or tisuue samples- non interventional study Project 2- FGFR typing in IO treated patients- Non interventional study
STRONGAn Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) – Core Protocol. https://clinicaltrials.gov/ct2/show/NCT03084471
TitanTCC_0146-ASGA phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma
UroFollow-Marker-gestützte Nachsorge von Patienten mit nicht-muskelinvasiven low/intermediate-risk Harnblasentumoren.
 
Kontakt

Erwachsenenurologie

Hochschulambulanz/ Abteilung minimal-invasive Urologie

Krankenhausstraße 12
91054 Erlangen

Sekretariat:
Telefon: 09131 85-33683, -33282, -42295 - Aufgrund von Personalmangel kann es aktuell zu verlängerten Wartezeiten kommen. Wir bitten dies zu entschuldigen.  
Fax: 09131 85-34851

Station CHZ-B2-2

Östliche Stadtmauerstraße 27 (Chirurgisches Zentrum)
Telefon: 09131 85-37062
Fax: 09131 85-37061

Standort Malteser Waldkrankenhaus St. Marien

Rathsberger Straße 57
91054 Erlangen

Sekretariat (Waldkrankenhaus):
Telefon: 09131 822-3178
Fax: 09131 822-3179

Sektion Kinderurologie

Sekretariat:
Telefon: 09131 85-33683
Fax: 09131 85-34851
Webseite

Station UR-2A

Kinder- und Jugendklinik
Loschgestraße 15
91054 Erlangen

Sektion Kinderurologie Sekretariat: Telefon: 09131 85-33683 Fax: 09131 85-34851 Webseite Station UR-2A Kinder- und Jugendklinik Loschgestraße 15 91054 Erlangen

Notfälle